FDA Approves First Biosimilar for Cancer Treatment Highlights SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. Curing AIDS, The Time Is Now: Gene-Editing Technology May Eliminate HIV
Company harnesses CRISPR-based gene editing technology as it enters human clinical trials to treat HIV.
4. Herpes Virus-Immunotherapy Combo Improves Melanoma Treatment
Patients with drug-resistant melanoma treated with a herpes virus-pembrolizumab drug combination showed a complete or partial response.
3. Microfluidic Device Tracks Long-term Evolution of Cancer Cells to Gain Insight into Metastasis
Device may reveal how to stop cancer cells from spreading.
2. Herceptin Biosimilar Demonstrates Equivalence in Comparative Phase 3 Study
Investigational trastuzumab biosimilar shows promise as potential lower cost treatment option to Herceptin for breast cancer and gastric cancer.
1. FDA Approves First Biosimilar for Treatment of Cancer
Bevacizumab-awwb, a biosimilar to Avastin, approved to treat several cancer types.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
Effectively Managing Immunizations in the Long-Term Care SettingSeptember 18th 2025
Creating a Culture of Quality in Fast-Melt Tablet DevelopmentSeptember 18th 2025
